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Conclusion
The use of combination antiplatelet therapy with aspirin
(ASA) and a thienopyridine has resulted in improved clin-
ical outcomes in patients with acute coronary syndromes
(ACS) and in those who undergo percutaneous coronary
interventions (PCI). The most appropriate dose of thienopy-
ridine therapy and its optimal duration of pretreatment and
administration post-PCI remain unknown. It appears that
platelet inhibitors are currently being used more aggres-
sively in patients at higher risk for further ischemic events,
such as patients with elevated troponin levels, or in those
who urgently undergo PCI. However, the ongoing shift
in platelet inhibition strategies in PCI toward the use of
higher clopidogrel loading doses, an increased time inter-
val for preprocedural loading, and an extended duration
of postprocedural clopidogrel treatment is symptomatic of
a current clinical situation where multiple unmet clinical
needs remain; most notably the problem of interindividual
variability and hyporesponse to platelet inhibition. Indeed,
it appears that one dosing strategy does not fit all patients
as it pertains to the use of platelet inhibitors.
Platelet function testing is an evolving tool that may
eventually become a practical method by which clinicians
can identify patients who are at increased risk for throm-
botic events. However, before these assays can be routinely
incorporated into clinical pathways, clinically meaningful
definitions of hyporesponse to antiplatelet therapy need to
be devised; also, there is a definite need for well-controlled
trials that support improved clinical effectiveness as a direct
result of therapeutic alteration based on laboratory values.
Novel platelet inhibitors in development possess altered
pharmacokinetic and pharmacodynamic profiles compared
with currently available thienopyridines. It has been hypoth-
esized that the use of platelet inhibitors with higher and less
variable inhibition of platelet aggregation will improve clini-
cians’ ability to prevent ischemic events following PCI. This
hypothesis was substantiated in a large Phase III trial to
assess improvement in therapeutic outcomes by optimizing
platelet inhibition with prasugrel-thrombolysis in myocar-
dial infarction (TRITON-TIMI 38). This trial assessed the
effectiveness of the novel thienopyridine, prasugrel, which
provided greater blockade of the platelet P2Y12 receptor
than clopidogrel in 13,608 patients with ACS scheduled to
undergo PCI. A 19% highly significant reduction of the com-
posite clinical endpoint (death, myocardial infarction, and
stroke) was observed, albeit at the cost of more serious
bleeding. Other newer compounds may potentially address
some of the shortcomings of currently available thienopy-
ridines by providing a more rapid onset of platelet inhibition
and more predictable and durable antiplatelet responses. It
is hoped that results from randomized controlled clinical
trials with these investigational agents will advance the field
by addressing the aforementioned clinically unmet needs.
Lastly, there remains a need to improve patient adherence
to prescribed antiplatelet strategies after ACS and PCI, and
also to prevent unnecessary and potentially catastrophic
early discontinuation of platelet inhibitors in patients who
have received drug-eluting stents.
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